Wenjin Yin
Clinical trials sponsored by Wenjin Yin, explained in plain language.
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThis study tests a new drug combination (Iparomlimab and Tuvonralimab, also called QL1706) in people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if it can slow down the cancer's growth. About 123 women will take part, and researchers will also che…
Phase: PHASE2 • Sponsor: Wenjin Yin • Aim: Disease control
Last updated May 02, 2026 05:46 UTC
-
Breast cancer drug schedule showdown: continuous or intermittent dosing?
Disease control Recruiting nowThis study compares taking pyrotinib continuously versus on an intermittent schedule for people with HER2-positive advanced breast cancer. About 186 adults whose cancer has spread or cannot be removed by surgery will be randomly assigned to one of the two dosing plans. The goal i…
Phase: PHASE2 • Sponsor: Wenjin Yin • Aim: Disease control
Last updated May 02, 2026 05:46 UTC
-
New hope for advanced breast cancer: real-world trial of targeted drug begins
Disease control Recruiting nowThis study is testing a drug called trastuzumab deruxtecan in 118 adults with advanced breast cancer. The goal is to see how long the drug can keep the cancer from growing and what side effects occur. Participants must be in good general health (ECOG 0-1) and not pregnant or nurs…
Sponsor: Wenjin Yin • Aim: Disease control
Last updated May 01, 2026 15:57 UTC